Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
We report here on the activity of tigecycline and comparators against multidrug-resistant (resistant to >or=3 antimicrobial classes; MDR) Enterobacteriaceae from the USA collected between January 2004 and January 2006 as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Nationally, 131 (5.9%) Escherichia coli, 174 (10.1%) Klebsiella pneumoniae, 4 (1.2%) Klebsiella oxytoca, 24 (4.9%) Enterobacter aerogenes, 126 (9.5%) Enterobacter cloacae and 20 (2.6%) Serratia marcescens isolates were MDR. Four isolates (two K. pneumoniae and two E. cloacae) were resistant to nine antimicrobials. Tigecycline performed well against MDR E. coli (MIC(90) 0.5 microg/mL, 0% resistant) and K. pneumoniae (MIC(90) 4 microg/mL, 9.2% resistant). A MIC(90) of 8 microg/mL was reported for tigecycline against the other MDR organisms studied here, notably lower than those of most comparators.
DiPersio
Joseph R
JR
SUMMA Health System Hospitals, Akron OH, USA. dipersij@summa-health.org
Dowzicky
Michael J
MJ
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D018550:Cephalosporin Resistance; D024901:Drug Resistance, Multiple, Bacterial; D004755:Enterobacteriaceae / Q000187:drug effects*; D004756:Enterobacteriaceae Infections / Q000453:epidemiology* / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D010641:Phenotype; D011159:Population Surveillance; D011786:Quality Control; D000078304:Tigecycline; D014481:United States / Q000453:epidemiology; D001618:beta-Lactamases / Q000378:metabolism
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D001618:beta-Lactamases; D008911:Minocycline